Savara Inc.(SVRA)

Biotechnology · Yardley, PA

$4.65-0.13 (-2.72%)

Delayed quote: Oct 6, 2026, 4:00 PM EDT

PE Ratio: N/A

Basis: FMP quote price / unrounded diluted EPS from four consecutive issuer fiscal quarters. Source: stored company filings and market data; unavailable inputs remain N/A.

The P/E ratio is N/A as of 2026-10-06T21:43:10.278Z.

Stored calculation inputs

Calculation as of: 2026-10-06T21:43:10.278Z.

Quote observation: 2026-10-06T20:00:00.000Z. Amounts in USD. The price header may show a later quote.

Quote price: 4.65
Unrounded diluted TTM EPS · period ending 2026-06-30: -0.58

FMP input reference: 91899883c476d55b2433093e583c87952940339a9b77bc55d8a3dd78c9ec7759

Forward PE Ratio|PEG Ratio|P/B Ratio|EPS|All Metrics

SVRA PE Ratio Metrics

PE RATIO

N/A

SVRA Competitors' PE Ratio

SVRA

Savara Inc.

Current

Market Cap

$952.91M

PE Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

AKTS

Aktis Oncology, Inc.

vs SVRA

Market Cap

$953.81M

PE Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

KURA

Kura Oncology, Inc.

vs SVRA

Market Cap

$934.79M

PE Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

PCRX

Pacira BioSciences, Inc.

vs SVRA

Market Cap

$973.93M

PE Ratio

70.48

TTM Avg

118.14

3Y Avg

119.36

5Y Avg

99.91

SPTX

Seaport Therapeutics, Inc. Common Stock

vs SVRA

Market Cap

$929.83M

PE Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

LTGO

Latigo Biotherapeutics Inc.

vs SVRA

Market Cap

$978.09M

PE Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

MGTX

MeiraGTx Holdings plc

vs SVRA

Market Cap

$981.66M

PE Ratio

14.93

TTM Avg

18.35

3Y Avg

18.35

5Y Avg

18.35

CBLL

CeriBell, Inc.

vs SVRA

Market Cap

$923.53M

PE Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

LBRX

LB Pharmaceuticals Inc Common Stock

vs SVRA

Market Cap

$982.46M

PE Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

MLTX

MoonLake Immunotherapeutics

vs SVRA

Market Cap

$921.06M

PE Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

NAME	MARKET CAP	PE RATIO	TTM	3Y	5Y
Savara Inc. (SVRA)	$952.91M	N/A	N/A	N/A	N/A
Aktis Oncology, Inc. (AKTS)vs ›	$953.81M	N/A	N/A	N/A	N/A
Kura Oncology, Inc. (KURA)vs ›	$934.79M	N/A	N/A	N/A	N/A
Pacira BioSciences, Inc. (PCRX)vs ›	$973.93M	70.48	118.14	119.36	99.91
Seaport Therapeutics, Inc. Common Stock (SPTX)vs ›	$929.83M	N/A	N/A	N/A	N/A
Latigo Biotherapeutics Inc. (LTGO)vs ›	$978.09M	N/A	N/A	N/A	N/A
MeiraGTx Holdings plc (MGTX)vs ›	$981.66M	14.93	18.35	18.35	18.35
CeriBell, Inc. (CBLL)vs ›	$923.53M	N/A	N/A	N/A	N/A
LB Pharmaceuticals Inc Common Stock (LBRX)vs ›	$982.46M	N/A	N/A	N/A	N/A
MoonLake Immunotherapeutics (MLTX)vs ›	$921.06M	N/A	N/A	N/A	N/A

P/E Comparison

Trailing P/E

N/A

Forward P/E

N/A

Forward P/E Calculation

View All Analyst Estimates

Forward P/E is calculated using analyst consensus EPS estimates for the current or next fiscal year.

Calculation:

Current Price

$4.65

Forward EPS (Est.)

$-0.94

Forward P/E

N/A

Source: FMP Analyst Consensus Estimates. Forward EPS represents the average analyst estimate for the nearest fiscal year.

PE Ratio Formula & Definition

PE Ratio = Share Price / Diluted EPS (TTM)

The price-to-earnings ratio measures how much investors pay for each dollar of trailing earnings. A lower PE can indicate a cheaper valuation; a higher PE implies higher growth expectations.

Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute

See the Lowest P/E Ratio Stocks ranking →

PE Ratio: N/A

SVRA PE Ratio Metrics

SVRA Competitors' PE Ratio

P/E Comparison

Forward P/E Calculation

PE Ratio Formula & Definition

Related Metrics